Although MTAP staining offers the benefit of labeling normal cells as an internal (positive) control, our work shows that it is not always a dependable surrogate marker for CDKN2A status, particularly in anaplastic meningiomas with differing CDKN2A and MTAP statuses. This evidence concerns the gene CDKN2A and meningioma.